Accelsiors CRO

𝗛𝗼𝘄 𝗱𝗼 𝘆𝗼𝘂 𝗮𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗲 𝘀𝘂𝗰𝗰𝗲𝘀𝘀 𝗶𝗻 𝗼𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹𝘀?    Oncology clinical trials are complex, but with 𝗔𝗰𝗰𝗲𝗹𝗲𝗥𝗢𝗨𝗧𝗘™, we’re rewriting the playbook: 𝗦𝘁𝗿𝗲𝗮𝗺𝗹𝗶𝗻𝗲𝗱 𝗘𝗳𝗳𝗶𝗰𝗶𝗲𝗻𝗰𝘆: Reducing timelines without compromising quality.  𝗜𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗲𝗱 𝗔𝗽𝗽𝗿𝗼𝗮𝗰𝗵: Four synchronized streams—oversight and management, startup acceleration, startup stream, and closure—designed for #oncology’s unique demands.  𝗗𝗮𝘁𝗮 𝗤𝘂𝗮𝗹𝗶𝘁𝘆 & 𝗖𝗼𝗺𝗽𝗹𝗶𝗮𝗻𝗰𝗲: Ensuring accuracy and regulatory adherence at every stage. 𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲 𝗮𝗯𝗼𝘂𝘁 𝗔𝗰𝗰𝗲𝗹𝗲𝗥𝗢𝗨𝗧𝗘™ and discover how we can help you overcome the challenges of 𝗼𝗻𝗰𝗼𝗹𝗼𝗴𝘆 clinical trials >> https://lnkd.in/dc8UZnEd  

For biotech companies, identifying the right market opportunities is essential to selecting the right #biosimilars. Let's explore the essential facts!

What an inspiring week at the National Association of Pharmacy Students - Serbia (NAPSer) Congress in Zlatibor! To all the incredible pharmacy students, dedicated faculty members, and innovative industry professionals who joined us – 𝒕𝒉𝒂𝒏𝒌 𝒚𝒐𝒖. Your passion and curiosity made this event extraordinary. A special thanks to our Nevena Arsic and Darko Mitrović for leading the workshop: “𝗙𝗿𝗼𝗺 𝗖𝗼𝗻𝗰𝗲𝗽𝘁 𝘁𝗼 𝗖𝘂𝗿𝗲: 𝗖𝗥𝗢𝘀 𝗶𝗻 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁.” Their insights on how Clinical Research Organizations transform innovative ideas into life-saving therapies sparked engaging conversations and meaningful connections. Thank you once again to everyone who made this event a success. Together, we are pushing the boundaries of what’s possible in pharmacy! We look forward to supporting and participating in future endeavors!

The FDA’s FY 2025 legislative goals 𝗮𝗿𝗲 𝘀𝗲𝘁 𝘁𝗼 𝘀𝗶𝗴𝗻𝗶𝗳𝗶𝗰𝗮𝗻𝘁𝗹𝘆 𝗿𝗲𝘀𝗵𝗮𝗽𝗲 the landscape for biologic therapies, simplifying the 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗽𝗿𝗼𝗰𝗲𝘀𝘀 and eliminating the distinction between #biosimilars and 𝗶𝗻𝘁𝗲𝗿𝗰𝗵𝗮𝗻𝗴𝗲𝗮𝗯𝗹𝗲 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝘀. This change will enhance access to essential medications while reducing confusion for both 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 and 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗽𝗿𝗼𝘃𝗶𝗱𝗲𝗿𝘀. The shift is particularly impactful in 𝗼𝗻𝗰𝗼𝗹𝗼𝗴𝘆, where rapid access to innovative treatments is critical. As a potential partner, we could collaborate in simplifying 𝗱𝗿𝘂𝗴 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗽𝗿𝗼𝗰𝗲𝘀𝘀𝗲𝘀, accelerating 𝗺𝗮𝗿𝗸𝗲𝘁 𝗲𝗻𝘁𝗿𝘆, and bringing 𝘁𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝘃𝗲 𝘀𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀 to patients faster. 𝗖𝗹𝗶𝗰𝗸 𝗵𝗲𝗿𝗲 𝘁𝗼 𝘀𝘁𝗮𝗿𝘁 𝘁𝗵𝗲 𝗰𝗼𝗻𝘃𝗲𝗿𝘀𝗮𝘁𝗶𝗼𝗻 >> https://lnkd.in/dnC_K_3p 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲 𝗮𝗯𝗼𝘂𝘁 𝘁𝗵𝗲 #FDA'𝘀 𝗙𝗬 𝟮𝟬𝟮𝟱 𝗽𝗹𝗮𝗻𝘀: https://lnkd.in/dhU7kAYM

Based on last week’s poll, we deliver based on your votes! 𝟱𝟯% 𝗼𝗳 𝘆𝗼𝘂𝗿 𝘃𝗼𝘁𝗲𝘀 𝗵𝗮𝘃𝗲 𝗰𝗹𝗲𝗮𝗿𝗹𝘆 𝗶𝗻𝗱𝗶𝗰𝗮𝘁𝗲𝗱 𝗮𝗻 𝗶𝗻𝘁𝗲𝗿𝗲𝘀𝘁 𝗶𝗻 𝗡𝗲𝘂𝗿𝗼𝗲𝗻𝗱𝗼𝗰𝗿𝗶𝗻𝗲 𝗧𝘂𝗺𝗼𝗿𝘀.  Over recent years, global oncology specialists have embraced 𝘁𝗮𝗶𝗹𝗼𝗿𝗲𝗱 𝗱𝗿𝘂𝗴 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 to treat NETs. These include:  • 𝗦𝗼𝗺𝗮𝘁𝗼𝘀𝘁𝗮𝘁𝗶𝗻 𝗮𝗻𝗮𝗹𝗼𝗴𝘂𝗲𝘀 to reduce hormone levels • 𝗖𝗵𝗲𝗺𝗼𝘁𝗵𝗲𝗿𝗮𝗽𝘆 to target cancer cells • 𝗧𝗮𝗿𝗴𝗲𝘁𝗲𝗱 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 designed to inhibit tumor growth What makes these treatments stand out? They’re 𝗽𝗲𝗿𝘀𝗼𝗻𝗮𝗹𝗶𝘇𝗲𝗱, often combined to achieve the best possible outcomes. Join us in advancing treatment options. Request a proposal at [email protected]   For more information on our oncology experience >> https://lnkd.in/dDyyEZuh 

Today, on #WorldAIDSDay, we stand in solidarity with the global community to raise awareness, and support those living with HIV. As a global CRO, we are committed to advancing clinical research that drives progress in HIV prevention, treatment, and care. Together, we can work towards a future without AIDS. #ClinicalResearch #HIVAwareness

We're happy to announce our participation in this year’s National Association of Pharmacy Students - Serbia (NAPSer) congress in Serbia!  🗓️𝗪𝗵𝗲𝗻? >>  4-8 December  📍𝗪𝗵𝗲𝗿𝗲? >> Student resort in Zlatibor Join us for an insightful workshop, "𝗙𝗿𝗼𝗺 𝗖𝗼𝗻𝗰𝗲𝗽𝘁 𝘁𝗼 𝗖𝘂𝗿𝗲: 𝗖𝗥𝗢𝘀 𝗶𝗻 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁", where Nevena Arsic, our Business Development Associate, and Darko Mitrović, our Senior Regulatory Affairs Associate, will uncover the vital role of CROs in transforming ideas into life-saving medicines. Don’t miss this chance to explore the world of clinical trials, engage in interactive Q&A sessions, and tackle real-world case studies. Discover career opportunities and current industry trends with Accelsiors. 𝗦𝗲𝗲 𝘆𝗼𝘂 𝘁𝗵𝗲𝗿𝗲! 💊 

Let’s shine a light on the rapidly expanding 𝗨.𝗦. 𝗶𝗻𝘀𝘂𝗹𝗶𝗻 𝗺𝗮𝗿𝗸𝗲𝘁 as we conclude U.S. Diabetes Awareness Month. It is estimated to reach 𝗨𝗦𝗗 𝟴.𝟱𝟰 𝗯𝗶𝗹𝗹𝗶𝗼𝗻 𝗶𝗻 𝟮𝟬𝟮𝟰 and is projected to grow to 𝗨𝗦𝗗 𝟯𝟭.𝟬𝟴 𝗯𝗶𝗹𝗹𝗶𝗼𝗻 𝗯𝘆 𝟮𝟬𝟯𝟰, with an impressive 𝗖𝗔𝗚𝗥 𝗼𝗳 𝟭𝟯.𝟳𝟵%. This growth is driven by the 𝗿𝗶𝘀𝗶𝗻𝗴 𝗽𝗿𝗲𝘃𝗮𝗹𝗲𝗻𝗰𝗲 𝗼𝗳 𝗱𝗶𝗮𝗯𝗲𝘁𝗲𝘀, especially among 𝘆𝗼𝘂𝗻𝗴𝗲𝗿 𝗽𝗼𝗽𝘂𝗹𝗮𝘁𝗶𝗼𝗻𝘀. Additionally, there is an increasing focus on creating personalized insulin therapies to more effectively address patients' needs.    Read our article in a dedicate Spark article, “𝗗𝗲𝗹𝘃𝗶𝗻𝗴 𝗶𝗻𝘁𝗼 𝘁𝗵𝗲 𝗗𝘆𝗻𝗮𝗺𝗶𝗰 𝗟𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲 𝗼𝗳 𝗣𝗲𝗱𝗶𝗮𝘁𝗿𝗶𝗰 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹𝘀”, to discover key insights that can help you understanding child-specific therapies. 𝗗𝗼𝘄𝗻𝗹𝗼𝗮𝗱 𝗵𝗲𝗿𝗲: https://lnkd.in/d3ZJrQ3f

🍂 𝗛𝗮𝗽𝗽𝘆 𝗧𝗵𝗮𝗻𝗸𝘀𝗴𝗶𝘃𝗶𝗻𝗴! 🍂 As we approach this special time of year, we want to take a moment to express our heartfelt gratitude to our incredible partners, colleagues, investigators and patients. Your unwavering support and collaboration inspire us every day. It is your commitment that drives our mission forward, and we are truly thankful for the opportunity to work alongside you in advancing clinical research and improving lives. Wishing you and your loved ones a warm and joyous #Thanksgiving filled with peace and gratitude. 𝗧𝗵𝗮𝗻𝗸 𝘆𝗼𝘂 𝗳𝗼𝗿 𝗯𝗲𝗶𝗻𝗴 𝗮 𝗽𝗮𝗿𝘁 𝗼𝗳 𝗼𝘂𝗿 𝗷𝗼𝘂𝗿𝗻𝗲𝘆! 🙏💙

As we wrap up U.S. Diabetes Awareness Month, let’s focus on the 𝗳𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗲𝗻𝗱𝗼𝗰𝗿𝗶𝗻𝗼𝗹𝗼𝗴𝘆 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗮𝗻𝗱 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹𝘀. Where do you see the greatest potential for innovation? 𝗪𝗲’𝗿𝗲 𝗲𝗮𝗴𝗲𝗿 𝘁𝗼 𝗵𝗲𝗮𝗿 𝘆𝗼𝘂𝗿 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀! Take a moment to share your thoughts in our poll. Together, we can drive meaningful changes in the endocrine health sector.